FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2017743982> ?p ?o ?g. }

• W2017743982 endingPage "39378" @default.
• W2017743982 startingPage "39370" @default.
• W2017743982 abstract "Equine herpesvirus-1 (EHV-1), an α-herpesvirus of the family Herpesviridae, causes respiratory disease, abortion, and encephalomyelitis in horses. EHV-1 utilizes equine MHC class I molecules as entry receptors. However, hamster MHC class I molecules on EHV-1-susceptible CHO-K1 cells play no role in EHV-1 entry. To identify the MHC class I molecule region that is responsible for EHV-1 entry, domain exchange and site-directed mutagenesis experiments were performed, in which parts of the extracellular region of hamster MHC class I (clone C5) were replaced with corresponding sequences from equine MHC class I (clone A68). Substitution of alanine for glutamine at position 173 (Q173A) within the α2 domain of the MHC class I molecule enabled hamster MHC class I C5 to mediate EHV-1 entry into cells. Conversely, substitution of glutamine for alanine at position 173 (A173Q) in equine MHC class I A68 resulted in loss of EHV-1 receptor function. Equine MHC class I clone 3.4, which possesses threonine at position 173, was unable to act as an EHV-1 receptor. Substitution of alanine for threonine at position 173 (T173A) enabled MHC class I 3.4 to mediate EHV-1 entry into cells. These results suggest that the amino acid residue at position 173 of the MHC class I molecule is involved in the efficiency of EHV-1 entry. Equine herpesvirus-1 (EHV-1), an α-herpesvirus of the family Herpesviridae, causes respiratory disease, abortion, and encephalomyelitis in horses. EHV-1 utilizes equine MHC class I molecules as entry receptors. However, hamster MHC class I molecules on EHV-1-susceptible CHO-K1 cells play no role in EHV-1 entry. To identify the MHC class I molecule region that is responsible for EHV-1 entry, domain exchange and site-directed mutagenesis experiments were performed, in which parts of the extracellular region of hamster MHC class I (clone C5) were replaced with corresponding sequences from equine MHC class I (clone A68). Substitution of alanine for glutamine at position 173 (Q173A) within the α2 domain of the MHC class I molecule enabled hamster MHC class I C5 to mediate EHV-1 entry into cells. Conversely, substitution of glutamine for alanine at position 173 (A173Q) in equine MHC class I A68 resulted in loss of EHV-1 receptor function. Equine MHC class I clone 3.4, which possesses threonine at position 173, was unable to act as an EHV-1 receptor. Substitution of alanine for threonine at position 173 (T173A) enabled MHC class I 3.4 to mediate EHV-1 entry into cells. These results suggest that the amino acid residue at position 173 of the MHC class I molecule is involved in the efficiency of EHV-1 entry. Equine herpesvirus-1 (EHV-1), 2The abbreviations used are: EHV-1equine herpesvirus-1gDglycoprotein Dp.i.postinfection. an α-herpesvirus of the family Herpesviridae, is the causative agent of respiratory disease, abortion, and a serious neurological disease known as encephalomyelitis in horses. Currently available vaccines are insufficient to protect against neurological disorders and abortions caused by EHV-1 (1Patel J.R. Heldens J. Vet. J. 2005; 170: 14-23Crossref PubMed Scopus (200) Google Scholar). Outbreaks of EHV-1 encephalomyelitis can devastate farms, riding schools, and veterinary hospitals (2Stierstorfer B. Eichhorn W. Schmahl W. Brandmüller C. Kaaden O.R. Neubauer A. J. Vet. Med. B Infect. Dis. Vet. Public Health. 2002; 49: 37-41Crossref PubMed Scopus (29) Google Scholar, 3Studdert M.J. Hartley C.A. Dynon K. Sandy J.R. Slocombe R.F. Charles J.A. Milne M.E. Clarke A.F. El-Hage C. Vet. Rec. 2003; 153: 417-423Crossref PubMed Scopus (45) Google Scholar, 4Kohn C.W. Reed S.M. Sofaly C.D. Henninger R.W. Saville W.J. Allen G.P. Premanadan C. Clin. Techniques Equine Practice. 2006; 5: 60-66Crossref Scopus (23) Google Scholar). Therefore, EHV-1 is one of the most important pathogens in the equine industry. equine herpesvirus-1 glycoprotein D postinfection. EHV-1 attaches to heparan sulfate on the cell surface (5Osterrieder N. Virus Res. 1999; 59: 165-177Crossref PubMed Scopus (59) Google Scholar, 6Sugahara Y. Matsumura T. Kono Y. Honda E. Kida H. Okazaki K. Arch. Virol. 1997; 142: 1849-1856Crossref PubMed Scopus (16) Google Scholar). Viral entry into cells occurs through either direct fusion at the plasma membrane or endocytosis (7Frampton Jr., A.R. Stolz D.B. Uchida H. Goins W.F. Cohen J.B. Glorioso J.C. J. Virol. 2007; 81: 10879-10889Crossref PubMed Scopus (51) Google Scholar, 8Hasebe R. Sasaki M. Sawa H. Wada R. Umemura T. Kimura T. Virology. 2009; 393: 198-209Crossref PubMed Scopus (28) Google Scholar). Among the viral glycoproteins that play important roles in EHV-1 entry, glycoprotein D (gD) is essential for viral entry in all cases (9Csellner H. Walker C. Wellington J.E. McLure L.E. Love D.N. Whalley J.M. Arch. Virol. 2000; 145: 2371-2385Crossref PubMed Scopus (47) Google Scholar, 10Frampton Jr., A.R. Goins W.F. Cohen J.B. von Einem J. Osterrieder N. O'Callaghan D.J. Glorioso J.C. J. Virol. 2005; 79: 3169-3173Crossref PubMed Scopus (24) Google Scholar, 11Whalley J.M. Ruitenberg K.M. Sullivan K. Seshadri L. Hansen K. Birch D. Gilkerson J.R. Wellington J.E. Arch. Virol. 2007; 152: 717-725Crossref PubMed Scopus (16) Google Scholar, 12Van de Walle G.R. Peters S.T. VanderVen B.C. O'Callaghan D.J. Osterrieder N. J. Virol. 2008; 82: 11859-11868Crossref PubMed Scopus (46) Google Scholar). Recently, the equine MHC class I molecule was identified as a host factor involved in the entry process of EHV-1 (13Kurtz B.M. Singletary L.B. Kelly S.D. Frampton Jr., A.R. J. Virol. 2010; 84: 9027-9034Crossref PubMed Scopus (35) Google Scholar, 14Sasaki M. Hasebe R. Makino Y. Suzuki T. Fukushi H. Okamoto M. Matsuda K. Taniyama H. Sawa H. Kimura T. Genes Cells. 2011; 16: 343-357Crossref PubMed Scopus (31) Google Scholar). NIH3T3 mouse fibroblast cells and B78H1 mouse melanoma cells are naturally resistant to EHV-1 infection; however, these cell lines become susceptible to EHV-1 infection by the exogenous expression of equine MHC class I (13Kurtz B.M. Singletary L.B. Kelly S.D. Frampton Jr., A.R. J. Virol. 2010; 84: 9027-9034Crossref PubMed Scopus (35) Google Scholar, 14Sasaki M. Hasebe R. Makino Y. Suzuki T. Fukushi H. Okamoto M. Matsuda K. Taniyama H. Sawa H. Kimura T. Genes Cells. 2011; 16: 343-357Crossref PubMed Scopus (31) Google Scholar). The equine MHC class I molecule interacts with EHV-1 gD and mediates EHV-1 entry into equine cell types that are naturally susceptible to EHV-1 infection (14Sasaki M. Hasebe R. Makino Y. Suzuki T. Fukushi H. Okamoto M. Matsuda K. Taniyama H. Sawa H. Kimura T. Genes Cells. 2011; 16: 343-357Crossref PubMed Scopus (31) Google Scholar). MHC class I molecules are known primarily for their role in presenting peptides from intracellular antigens to cytotoxic T cells. MHC class I is polygenic and polymorphic (15Janeway C.A. Travers P. Walport M. Shlomchik M. Immunobiology. 6th Ed. Garland Science Publishing, New York2005: 169-201Google Scholar). Fifty equine MHC class I genes were identified among 10 different serologically defined equine MHC class I haplotypes (16Tallmadge R.L. Campbell J.A. Miller D.C. Antczak D.F. Immunogenetics. 2010; 62: 159-172Crossref PubMed Scopus (41) Google Scholar), and seven MHC class I loci were transcribed in an MHC homozygous individual (17Tallmadge R.L. Lear T.L. Antczak D.F. Immunogenetics. 2005; 57: 763-774Crossref PubMed Scopus (45) Google Scholar). Although previous studies have shown that three equine MHC class I molecules can act as EHV-1 receptors (13Kurtz B.M. Singletary L.B. Kelly S.D. Frampton Jr., A.R. J. Virol. 2010; 84: 9027-9034Crossref PubMed Scopus (35) Google Scholar, 14Sasaki M. Hasebe R. Makino Y. Suzuki T. Fukushi H. Okamoto M. Matsuda K. Taniyama H. Sawa H. Kimura T. Genes Cells. 2011; 16: 343-357Crossref PubMed Scopus (31) Google Scholar), it is unclear whether all MHC class I molecules are involved in EHV-1 infection. Chinese hamster ovary (CHO)-K1 cells are known to be susceptible to EHV-1 infection (10Frampton Jr., A.R. Goins W.F. Cohen J.B. von Einem J. Osterrieder N. O'Callaghan D.J. Glorioso J.C. J. Virol. 2005; 79: 3169-3173Crossref PubMed Scopus (24) Google Scholar). Unlike equine cells, inhibition of the cell surface expression of MHC class I molecules by β2-microglobulin knockdown does not reduce the susceptibility of CHO-K1 cells to EHV-1 infection (14Sasaki M. Hasebe R. Makino Y. Suzuki T. Fukushi H. Okamoto M. Matsuda K. Taniyama H. Sawa H. Kimura T. Genes Cells. 2011; 16: 343-357Crossref PubMed Scopus (31) Google Scholar). This result suggests that hamster MHC class I has no role in EHV-1 entry into CHO-K1 cells. In this study, we expressed hamster MHC class I on NIH3T3 cells and confirmed the inability of hamster MHC class I to mediate the cellular entry of EHV-1. To clarify the region of equine MHC class I responsible for EHV-1 entry, we performed domain exchange and site-directed mutagenesis experiments on the hamster MHC class I backbone, in which parts of the extracellular region were replaced with corresponding sequences from equine MHC class I. Results from these experiments revealed an important amino acid residue of MHC class I that mediates the efficiency of EHV-1 entry, as well as an equine MHC class I gene that does not act as a receptor for EHV-1. NIH3T3 and 293T cells were cultured in DMEM containing 10% FBS. The EHV-1 mutant Ab4-GFP contains a GFP expression cassette between open reading frame (ORF) 62 and ORF 63 (18Ibrahim el S.M. Pagmajav O. Yamaguchi T. Matsumura T. Fukushi H. Microbiol. Immunol. 2004; 48: 831-842Crossref PubMed Scopus (13) Google Scholar). Stock viruses were cultured in equine dermis cells and were titrated by plaque formation assay on rabbit kidney (RK13) cells. Equine MHC class I heavy chain clones A68 and B118 were described previously (14Sasaki M. Hasebe R. Makino Y. Suzuki T. Fukushi H. Okamoto M. Matsuda K. Taniyama H. Sawa H. Kimura T. Genes Cells. 2011; 16: 343-357Crossref PubMed Scopus (31) Google Scholar). Equine MHC class I heavy chain clone 3.4 (GenBank accession number XM_001493795) cDNA) was obtained by RT-PCR from a primary cultured equine brain microvascular endothelial cell cDNA library (14Sasaki M. Hasebe R. Makino Y. Suzuki T. Fukushi H. Okamoto M. Matsuda K. Taniyama H. Sawa H. Kimura T. Genes Cells. 2011; 16: 343-357Crossref PubMed Scopus (31) Google Scholar). Hamster MHC class I heavy chain clone C5 (GenBank accession number AY064390) cDNA was obtained by RT-PCR from CHO-K1 cells. These cDNA fragments were cloned into the pCXSN vector (14Sasaki M. Hasebe R. Makino Y. Suzuki T. Fukushi H. Okamoto M. Matsuda K. Taniyama H. Sawa H. Kimura T. Genes Cells. 2011; 16: 343-357Crossref PubMed Scopus (31) Google Scholar). pCXSN-FLAG-A68, pCXSN-FLAG-B118, and pCXSN-HA-C5 were constructed by insertion of the FLAG or HA epitope tag between the putative signal sequence and the remaining coding sequence. Equine and hamster MHC class I domain-exchanged mutants were generated with the In-Fusion Advantage PCR Cloning kit (Clontech) in accordance with the manufacturer's instructions. Amino acid substitutions in MHC class I were introduced by PCR-mediated site-directed mutagenesis. NIH3T3 cells seeded in 24-well plates were transfected with plasmid DNA encoding MHC class I or its mutant by using Lipofectamine 2000 (Invitrogen). At 24 h after transfection, cells were infected with Ab4-GFP at a multiplicity of infection of 10. At 12 h postinfection (p.i.), GFP-expressing cells were observed under an inverted fluorescence microscope (IX70; Olympus, Tokyo, Japan) and counted by flow cytometry. For neutralization of viral gD, EHV-1 Ab4-GFP at a multiplicity of infection of 10 was incubated with anti-gD rabbit polyclonal antibody (generated in the author's laboratory) or control rabbit IgG (Beckman Coulter) for 30 min at 37 °C and then added to the cells. After incubation for 1 h, extracellular virus was inactivated by treatment with 0.1 m citrate buffer, pH 3.0. The cells were cultured in fresh growth medium for an additional 12 h p.i. Viral entry was assessed by counting the number of GFP-positive cells with flow cytometry. Soluble gD-Ig fusion protein (gD-Ig) consisting of the extracellular domain of EHV-1 gD and the Fc segment of the human IgG1 was generated as described previously (14Sasaki M. Hasebe R. Makino Y. Suzuki T. Fukushi H. Okamoto M. Matsuda K. Taniyama H. Sawa H. Kimura T. Genes Cells. 2011; 16: 343-357Crossref PubMed Scopus (31) Google Scholar). Purified human IgG (Invitrogen) was used as a control (control-Ig). NIH3T3 cells were plated in 12-well plates and transiently transfected with expression plasmids with Lipofectamine 2000 (Invitrogen). 293T cells were plated in 12-well plates and cotransfected with equine MHC class I and equine β2-microglobulin expression plasmids with TransIT-2020 (Mirus Bio, Madison, WI). After transfection, cells were stained with primary mouse mAbs against FLAG (clone M2; Sigma), HA (clone HA-7; Sigma), or equine MHC class I (clone H58A; VMRD, Pullman, WA). Bound antibodies were visualized by the addition of Alexa Fluor 488-conjugated anti-mouse IgG antibody (Invitrogen). Flow cytometric analysis was performed with a FACS Canto system (BD Biosciences). The data collected were analyzed with the Flowjo software package (Tree Star, Ashland, OR). To assess the binding of the gD-Ig fusion protein to equine MHC class I, cells were detached and incubated with gD-Ig or control-Ig at 4 °C for 30 min. Bound gD-Ig or control-Ig was stained with phycoerythrin-conjugated anti-human IgG antibody (Beckman Coulter). The fluorescence signal was analyzed by flow cytometry. 293T cells plated in poly-l-lysine-coated 48-well plates were cotransfected with the indicated equine MHC class I and equine β2-microglobulin expression plasmids as described above. After 20 h, cells were incubated with serially diluted gD-Ig or control-Ig in DMEM containing 10% FBS and 20 mm HEPES, pH 7.4, for 30 min at room temperature. The cells were washed with PBS containing 0.1% BSA and fixed with PBS containing 4% paraformaldehyde and 0.2% glutaraldehyde. Fixed cells were exposed to HRP-conjugated anti-human IgG antibody (Jackson ImmunoResearch, West Grove, PA). Signals were developed by adding o-phenylenediamine dihydrochloride substrate (Sigma) in phosphate-citrate buffer, pH 5.0. After addition of 3 n HCl, the absorbance at 490 nm was measured with a microplate reader (Bio-Rad). 293T cells were cotransfected with indicated equine MHC class I and equine β2-microglobulin expression plasmids as described above. After 36 h, cells were lysed in a lysis buffer (1% Brij 98, 200 mm NaCl, 20 mm Tris-HCl, pH 7.5, 5 mm EDTA, 5% glycerol, and Complete protease inhibitor mixture (Roche Applied Science). Lysates were immunoprecipitated with Dynabeads Protein A (Invitrogen) for 2 h at 4 °C after coating with gD-Ig or control-Ig. After washing with lysis buffer, precipitated protein complexes were eluted by boiling in SDS-PAGE sample buffer and separated by SDS-PAGE. Proteins were transferred onto Immobilon-P transfer membranes (Millipore) and detected with anti-DYKDDDDK (FLAG tag) monoclonal antibody (clone L5; BioLegend, San Diego, CA) or anti-human IgG antibody (Jackson ImmunoResearch). A homology model of equine MHC class I A68 was constructed based on the crystal structure of HLA-B (Protein Data Bank code 2BVO). After 100 models were generated by Modeler 9v6 (19Eswar N. John B. Mirkovic N. Fiser A. Ilyin V.A. Pieper U. Stuart A.C. Marti-Renom M.A. Madhusudhan M.S. Yerkovich B. Sali A. Nucleic Acids Res. 2003; 31: 3375-3380Crossref PubMed Scopus (388) Google Scholar), a model was chosen by a combination of the Modeler objective function value and the discrete optimized protein energy statistical potential score (20Shen M.Y. Sali A. Protein Sci. 2006; 15: 2507-2524Crossref PubMed Scopus (1792) Google Scholar). After the addition of hydrogen atoms, the model was refined by energy minimization with the CHARMm force field and the Discovery Studio 2.5 software package (Accelrys, San Diego, CA). Steepest descent followed by conjugate gradient minimizations was carried out until the root mean square gradient was ≤0.01 kcal/mol per A. The generalized Born implicit solvent model (21Still W.C. Tempczyk A. Hawley R.C. Hendrickson T. J. Am. Chem. Soc. 1990; 112: 6127-6129Crossref Scopus (3363) Google Scholar, 22Tsui V. Case D.A. Biopolymers. 2000; 56: 275-291Crossref PubMed Scopus (857) Google Scholar) was used to model the effects of solvation. The molecular model was evaluated with PROCHECK (23Laskowski R.A. MacArthur M.W. Moss D.S. Thornton J.M. J. Appl. Crystallog. 1993; 26: 283-291Crossref Google Scholar) and VERIFY-3D (24Eisenberg D. Lüthy R. Bowie J.U. Methods Enzymol. 1997; 277: 396-404Crossref PubMed Scopus (1679) Google Scholar), and the model structure was displayed by PyMOL (25DeLano W.L. The PyMOL Molecular Graphics System. DeLano Scientific, San Carlos, CA2002Google Scholar). We obtained the hamster MHC class I heavy chain clone C5 cDNA (26Furukawa H. Iizuka K. Poursine-Laurent J. Shastri N. Yokoyama W.M. J. Immunol. 2002; 169: 126-136Crossref PubMed Scopus (49) Google Scholar) from CHO-K1 cells. C5 showed 70% amino acid sequence identity and 94% similarity with the equine MHC class I heavy chain clone A68, which we previously identified as an EHV-1 receptor. NIH3T3 cells are naturally resistant to EHV-1 infection (14Sasaki M. Hasebe R. Makino Y. Suzuki T. Fukushi H. Okamoto M. Matsuda K. Taniyama H. Sawa H. Kimura T. Genes Cells. 2011; 16: 343-357Crossref PubMed Scopus (31) Google Scholar); however, exogenous expression of FLAG-tagged A68 rendered the cells susceptible to infection by the GFP-expressing EHV-1 mutant strain Ab4-GFP (Fig. 1A). By contrast, no GFP signal was observed in NIH3T3 cells transfected with HA-tagged C5 (Fig. 1A). Cell surface expressions of A68 and C5 were confirmed by staining with anti-FLAG and anti-HA tag antibodies, respectively (Fig. 1A). These data suggest that the hamster MHC class I clone C5 expressed on the NIH3T3 cell surface does not mediate EHV-1 entry. MHC class I heavy chain is a type I transmembrane protein composed of three extracellular domains (α1, α2, and α3), a transmembrane domain, and a cytoplasmic tail (27Bjorkman P.J. Parham P. Annu. Rev. Biochem. 1990; 59: 253-288Crossref PubMed Scopus (621) Google Scholar). To identify the domain responsible for EHV-1 entry, we constructed three mutants, C5A68(α1), C5A68(α2), and C5A68(α3), in which each extracellular domain of C5 was exchanged with that of A68 (Fig. 1B). The expression level of the C5A68(α1) mutant on the NIH3T3 cell surface was relatively low compared with that of the C5A68(α2) and C5A68(α3) mutants (Fig. 1C). Among those three mutants, only C5A68(α2) supported EHV-1 entry into NIH3T3 cells (Fig. 1, C and D). We then constructed four additional C5 mutants, C5A68(115–161), C5A68(162–206), C5A68(162–187), and C5A68(188–206), in which each segment of the α2 domain was substituted with the corresponding region of A68 (Fig. 1B). Entry of Ab4-GFP occurred in NIH3T3 cells expressing C5A68(162–206) or C5A68(162–187), but not in NIH3T3 cells expressing C5A68(115–161) or C5A68(188–206) (Fig. 1, C and D). These results suggest that the amino acid residues at positions 162–187 of A68 play a role in EHV-1 receptor function. Between amino acid residues at positions 162 and 186, A68 and C5 differ in four positions (Fig. 2A). To identify the amino acid residues responsible for function of the EHV-1 receptor, we mutated these four positions individually in C5 (Fig. 2A). All of these C5 mutants were expressed on the NIH3T3 cell surface upon transfection; however, the EHV-1 entry was observed only in NIH3T3 cells expressing C5 Q173A (Fig. 2, B and C). We previously demonstrated the involvement of EHV-1 gD in equine MHC class I-mediated EHV-1 entry (14Sasaki M. Hasebe R. Makino Y. Suzuki T. Fukushi H. Okamoto M. Matsuda K. Taniyama H. Sawa H. Kimura T. Genes Cells. 2011; 16: 343-357Crossref PubMed Scopus (31) Google Scholar). To examine whether EHV-1 gD is also involved in viral entry via C5 Q173A, we tested the ability of anti-gD polyclonal antibody to block the EHV-1 infection of C5 Q173A-expressing cells. Anti-gD inhibited EHV-1 entry into C5 Q173A-expressing cells in a dose-dependent manner (Fig. 2D). These results indicate that the hamster MHC class I C5 Q173A mutant acts as a weak receptor for EHV-1. We next constructed a series of A68 mutants with replacement of amino acid residues at positions between 162 and 186 of A68 with those of C5 (summarized in Fig. 3A) and examined the susceptibility of NIH3T3 cells transfected with these mutants to EHV-1 infection. The W171L mutation reduced cell surface expression of A68 and inhibited viral entry into NIH3T3 cells (Fig. 3, B and C). The A173Q mutation drastically decreased EHV-1 receptor function, although similar levels of cell surface expression were observed between A68 A173Q and other mutants (Fig. 3, B and C). By contrast, EHD178DRQ and N182A did not impair EHV-1 receptor function (Fig. 3, B and C). A previous study showed that another equine MHC class I clone (B118) also acts as an EHV-1 receptor (14Sasaki M. Hasebe R. Makino Y. Suzuki T. Fukushi H. Okamoto M. Matsuda K. Taniyama H. Sawa H. Kimura T. Genes Cells. 2011; 16: 343-357Crossref PubMed Scopus (31) Google Scholar). The amino acid sequence of B118 showed high similarity to that of A68 (84% identity, 96% similarity), and the alanine residue at position 170 in B118 was equivalent to the alanine residue at position 173 in A68 (Fig. 4A). Induction of the A170Q mutation in B118 greatly decreased the efficiency of EHV-1 entry, although both B118 and B118 A170Q displayed comparable cell surface expression levels (Fig. 4, B and C). These mutagenesis studies reveal that a single amino acid within the α2 domain of equine MHC class I is important for the efficient entry of EHV-1. Because equine MHC class I mediates viral entry via its interaction with EHV-1 gD (14Sasaki M. Hasebe R. Makino Y. Suzuki T. Fukushi H. Okamoto M. Matsuda K. Taniyama H. Sawa H. Kimura T. Genes Cells. 2011; 16: 343-357Crossref PubMed Scopus (31) Google Scholar), we investigated the influence of the A173Q mutation on the binding of A68 with EHV-1 gD, using a soluble gD-Ig fusion protein consisting of the extracellular domain of EHV-1 gD and the Fc segment of human IgG1. Flow cytometric analysis showed that the interaction of gD-Ig with A68 A173Q was much weaker than that with A68, although the level of cell surface expression of A68 A173Q was comparable with that of wild-type A68 (Fig. 5A). Similarly, the A170Q mutation in B118 resulted in a greatly reduced affinity for EHV-1 gD (Fig. 5A). To examine further the effect of the A173Q mutation on the interaction between A68 and gD, cell-based ELISA and immunoprecipitation assays were performed with A68 or A68 A173Q-expressing cells. Cell-based ELISA showed that gD-Ig bound to A68-expressing cells in a dose-dependent manner (Fig. 5B). By contrast, gD-Ig did not bind to A68 A173Q-expressing cells (Fig. 5B). Interaction of gD-Ig with A68, but not with A68 A173Q, was observed by immunoprecipitation using gD-Ig (Fig. 5C). These results suggest that substitution of a glutamine residue for alanine at position 173 in A68 (or at position 170 in B118) deprives equine MHC class I of gD-binding capacity, which is required for MHC class I to act as an EHV-1 receptor. Because no crystal structures of equine MHC class I molecules are available, homology modeling of the extracellular domain of the equine MHC class I A68 was performed based on the crystal structure of human MHC class I HLA-B (Protein Data Bank code 2BVO). The alanine residue at position 173 was part of an α-helical structure in the α2 domain and was located near the apical surface of equine MHC class I A68 (Fig. 6). We investigated the effect of mutations at position 173 in A68 to amino acids of various hydrophobicities. These mutants displayed comparable cell surface expression levels (data not shown). The alanine residue has a hydrophobic side chain. Replacement of the alanine at position 173 in A68 by valine or methionine, which are also hydrophobic, had little effect on the function of the EHV-1 receptor (Fig. 7). Replacement of the alanine at position 173 by glutamine, which is relatively hydrophilic, greatly decreased the EHV-1 receptor function (Fig. 7). Replacement of alanine by more hydrophilic amino acids (A173T, A173S, A173E, and A173N) greatly decreased activity of the EHV-1 receptor (Fig. 7). These results suggest that the hydrophobicity of the amino acid at residue 173 of equine MHC class I may be involved in the ability of MHC class I to act as an EHV-1 receptor. Some equine MHC class I genes reportedly have valine, glutamic acid, or threonine instead of alanine at the position corresponding to position 173 of A68 (16Tallmadge R.L. Campbell J.A. Miller D.C. Antczak D.F. Immunogenetics. 2010; 62: 159-172Crossref PubMed Scopus (41) Google Scholar). Among the equine MHC class I nucleotide sequences registered in GenBank, we successfully obtained the equine MHC class I clone 3.4 cDNA, which has a threonine residue at position 173, from primary equine cells by RT-PCR (Fig. 8A). NIH3T3 cells transfected with equine MHC class I clone 3.4 were not susceptible to EHV-1 infection, although surface expression on NIH3T3 cells was confirmed by flow cytometry with an anti-equine MHC class I antibody (Fig. 8, B and C). To determine whether the threonine residue at position 173 of clone 3.4 is involved in the inability of this clone to act as an EHV-1 receptor, the T173A mutation was induced in clone 3.4. As expected, NIH3T3 cells expressing equine MHC class I clone 3.4 T173A showed susceptibility to EHV-1 infection (Fig. 8, B and C). Furthermore, preincubation of the virus with anti-gD polyclonal antibody reduced EHV-1 entry into equine MHC class I clone 3.4 T173A-expressing cells (Fig. 8D). These data suggest that equine MHC class I clone 3.4, which is expressed naturally on equine cells, is unable to function as an EHV-1 receptor. The findings also suggest that the residue at position 173 of equine MHC class I is involved in the efficiency of EHV-1 entry into cells. The present study revealed that a single amino acid at position 173 of equine MHC class I plays an important role in the entry of EHV-1. Although hamster MHC class I C5 showed amino acid sequence similarity to A68, C5 was unable to mediate EHV-1 entry into cells. A glutamine to alanine substitution at position 173 enabled C5 to act as an EHV-1 receptor, whereas an alanine to glutamine substitution at position 173 in equine MHC class I A68 resulted in loss of the EHV-1 receptor function. The importance of the amino acid residue at position 173 of equine MHC class I is further suggested by the finding that an alanine substitution at position 173 of equine MHC class I clone 3.4 (which does not naturally work as an EHV-1 receptor) resulted in the acquisition of EHV-1 receptor function. Equine MHC class I reacts with EHV-1 gD, and this interaction mediates EHV-1 entry into cells (14Sasaki M. Hasebe R. Makino Y. Suzuki T. Fukushi H. Okamoto M. Matsuda K. Taniyama H. Sawa H. Kimura T. Genes Cells. 2011; 16: 343-357Crossref PubMed Scopus (31) Google Scholar). Soluble gD-Ig fusion protein bound to equine MHC class I A68 and B118 on the cell surface. However, a mutation of alanine at position 173 in A68 or at position 170 in B118 impaired the interaction of gD-Ig with A68 or B118, respectively. These results indicate that these residues are directly involved in binding to EHV-1 gD and thereby influence EHV-1 receptor function. Although EHV-1 infection occurred in NIH3T3 cells expressing hamster MHC class I C5 or equine MHC class I clone 3.4 with an alanine substitution at position 173, the infection rate was lower than that in NIH3T3 cells expressing equine MHC class I clone A68. This finding suggests that other amino acid residues, in addition to alanine 173, contribute to EHV-1 receptor function. MHC class I molecules are polymorphic and broadly distributed in mammalian bodies (15Janeway C.A. Travers P. Walport M. Shlomchik M. Immunobiology. 6th Ed. Garland Science Publishing, New York2005: 169-201Google Scholar). Tallmadge et al. (16Tallmadge R.L. Campbell J.A. Miller D.C. Antczak D.F. Immunogenetics. 2010; 62: 159-172Crossref PubMed Scopus (41) Google Scholar) cloned 50 equine MHC class I genes from 10 different MHC class I haplotypes and classified their deduced amino acid sequences. Based on the amino acid alignment, 32 of the 50 genes have alanine at the position corresponding to position 173 of A68. In addition to A68 and B118, which we previously identified as an EHV-1 receptor, another equine MHC class I molecule (GenBank accession number XM_001915759) that reportedly mediates EHV-1 entry has alanine at the position corresponding to position 173 of A68 (13Kurtz B.M. Singletary L.B. Kelly S.D. Frampton Jr., A.R. J. Virol. 2010; 84: 9027-9034Crossref PubMed Scopus (35) Google Scholar). In this study, we showed that equine MHC class I clone 3.4 is unable to act as an EHV-1 receptor, and we further showed that threonine at position 173 is involved in the nonfunction as an EHV-1 receptor. Although the ability of other equine MHC class I molecules to mediate EHV-1 entry remains unclear, our findings suggest that EHV-1 utilizes a subset of equine MHC class I molecules in viral entry into equine cells. The extracellular region of MHC class I heavy chain is composed of three domains (α1, α2, and α3), and the α1 and α2 domains lie at the tip of MHC class I (27Bjorkman P.J. Parham P. Annu. Rev. Biochem. 1990; 59: 253-288Crossref PubMed Scopus (621) Google Scholar). Our molecular model suggests that the residue at position 173 within the α2 domain of A68 protrudes outside, as it is accessible to virus. It will be interesting to investigate how the amino acid residue at position 173 contributes to the interaction between MHC class I and EHV-1. Our substitution experiment suggests that the hydrophobicity of the amino acid at residue 173 may influence the efficiency of the MHC class I-dependent entry of EHV-1. In this work, we identified an amino acid residue in the α2 domain of equine MHC class I as a determinant involved in the efficiency of EHV-1 entry into cells. To understand further the interaction between EHV-1 and equine MHC class I molecules, structural determination of the complex formed by EHV-1 and equine MHC class I will be needed. The current work opens the way toward understanding the interaction between EHV-1 and equine MHC class I molecules at the molecular level and provides new insights into the host-virus interaction of EHV-1 infection. We thank Dr. Hisashi Arase (Osaka University, Osaka, Japan) for the pME18S expression vector that was used to generate the soluble gD-Ig fusion protein and Satoko Yamanouchi and Misato Yuyama for technical assistance." @default.
• W2017743982 created "2016-06-24" @default.
• W2017743982 creator A5001737851 @default.
• W2017743982 creator A5013790579 @default.
• W2017743982 creator A5024017884 @default.
• W2017743982 creator A5036254009 @default.
• W2017743982 creator A5037041497 @default.
• W2017743982 creator A5039244520 @default.
• W2017743982 creator A5067457491 @default.
• W2017743982 creator A5069668883 @default.
• W2017743982 date "2011-11-01" @default.
• W2017743982 modified "2023-09-28" @default.
• W2017743982 title "Single Amino Acid Residue in the A2 Domain of Major Histocompatibility Complex Class I Is Involved in the Efficiency of Equine Herpesvirus-1 Entry" @default.
• W2017743982 cites W1986191025 @default.
• W2017743982 cites W1986733964 @default.
• W2017743982 cites W1989228404 @default.
• W2017743982 cites W1999613945 @default.
• W2017743982 cites W2014565491 @default.
• W2017743982 cites W2018324683 @default.
• W2017743982 cites W2035667153 @default.
• W2017743982 cites W2039300794 @default.
• W2017743982 cites W2040800793 @default.
• W2017743982 cites W2045075275 @default.
• W2017743982 cites W2047730466 @default.
• W2017743982 cites W2057571516 @default.
• W2017743982 cites W2058067802 @default.
• W2017743982 cites W2059395820 @default.
• W2017743982 cites W2080203891 @default.
• W2017743982 cites W2082413848 @default.
• W2017743982 cites W2089734263 @default.
• W2017743982 cites W2104977132 @default.
• W2017743982 cites W2117140759 @default.
• W2017743982 cites W2121067996 @default.
• W2017743982 cites W2151477100 @default.
• W2017743982 cites W2153918116 @default.
• W2017743982 cites W2156879354 @default.
• W2017743982 cites W2167727704 @default.
• W2017743982 cites W2168770860 @default.
• W2017743982 doi "https://doi.org/10.1074/jbc.m111.251751" @default.
• W2017743982 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3234761" @default.
• W2017743982 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21949188" @default.
• W2017743982 hasPublicationYear "2011" @default.
• W2017743982 type Work @default.
• W2017743982 sameAs 2017743982 @default.
• W2017743982 citedByCount "11" @default.
• W2017743982 countsByYear W20177439822012 @default.
• W2017743982 countsByYear W20177439822013 @default.
• W2017743982 countsByYear W20177439822014 @default.
• W2017743982 countsByYear W20177439822016 @default.
• W2017743982 countsByYear W20177439822019 @default.
• W2017743982 countsByYear W20177439822020 @default.
• W2017743982 countsByYear W20177439822022 @default.
• W2017743982 countsByYear W20177439822023 @default.
• W2017743982 crossrefType "journal-article" @default.
• W2017743982 hasAuthorship W2017743982A5001737851 @default.
• W2017743982 hasAuthorship W2017743982A5013790579 @default.
• W2017743982 hasAuthorship W2017743982A5024017884 @default.
• W2017743982 hasAuthorship W2017743982A5036254009 @default.
• W2017743982 hasAuthorship W2017743982A5037041497 @default.
• W2017743982 hasAuthorship W2017743982A5039244520 @default.
• W2017743982 hasAuthorship W2017743982A5067457491 @default.
• W2017743982 hasAuthorship W2017743982A5069668883 @default.
• W2017743982 hasBestOaLocation W20177439821 @default.
• W2017743982 hasConcept C104317684 @default.
• W2017743982 hasConcept C134306372 @default.
• W2017743982 hasConcept C159047783 @default.
• W2017743982 hasConcept C185592680 @default.
• W2017743982 hasConcept C207936829 @default.
• W2017743982 hasConcept C2781338088 @default.
• W2017743982 hasConcept C33923547 @default.
• W2017743982 hasConcept C36503486 @default.
• W2017743982 hasConcept C515207424 @default.
• W2017743982 hasConcept C55493867 @default.
• W2017743982 hasConcept C86803240 @default.
• W2017743982 hasConceptScore W2017743982C104317684 @default.
• W2017743982 hasConceptScore W2017743982C134306372 @default.
• W2017743982 hasConceptScore W2017743982C159047783 @default.
• W2017743982 hasConceptScore W2017743982C185592680 @default.
• W2017743982 hasConceptScore W2017743982C207936829 @default.
• W2017743982 hasConceptScore W2017743982C2781338088 @default.
• W2017743982 hasConceptScore W2017743982C33923547 @default.
• W2017743982 hasConceptScore W2017743982C36503486 @default.
• W2017743982 hasConceptScore W2017743982C515207424 @default.
• W2017743982 hasConceptScore W2017743982C55493867 @default.
• W2017743982 hasConceptScore W2017743982C86803240 @default.
• W2017743982 hasIssue "45" @default.
• W2017743982 hasLocation W20177439821 @default.
• W2017743982 hasLocation W20177439822 @default.
• W2017743982 hasLocation W20177439823 @default.
• W2017743982 hasLocation W20177439824 @default.
• W2017743982 hasLocation W20177439825 @default.
• W2017743982 hasOpenAccess W2017743982 @default.
• W2017743982 hasPrimaryLocation W20177439821 @default.
• W2017743982 hasRelatedWork W1487857142 @default.
• W2017743982 hasRelatedWork W1702322095 @default.
• W2017743982 hasRelatedWork W1865764402 @default.
• W2017743982 hasRelatedWork W1975114493 @default.
• W2017743982 hasRelatedWork W2063728635 @default.

• next